GenomeKey is pioneering advancements in the field of diagnostics with its next-generation in vitro diagnostic (IVD) device designed to combat sepsis, a critical global health issue. This innovative device can rapidly detect and identify bacteria directly from patient blood samples, providing a comprehensive antimicrobial resistance (AMR) profile within hours, as opposed to the days required by traditional methods. By delivering timely and accurate results, GenomeKey aims to empower clinicians to administer the appropriate antibiotics swiftly, thereby improving patient outcomes and potentially saving lives. The device is designed to be low-cost and easily integrated into existing healthcare systems, ensuring accessibility for a wide range of medical facilities.

In collaboration with Oxford Nanopore Technologies, GenomeKey is enhancing its diagnostic capabilities through advanced sequencing technology. This partnership allows for the analysis of native DNA or RNA, enabling the rapid detection and evaluation of antimicrobial susceptibility. The integration of real-time data from Oxford Nanopore's platform is expected to set new standards in the management and treatment of sepsis, addressing the urgent need for effective diagnostics in a healthcare crisis that affects millions globally. By leveraging cutting-edge AI and machine learning, GenomeKey is committed to transforming the diagnostic landscape, ultimately aiming to reduce the human and financial toll of sepsis and improve overall healthcare outcomes.

United Kingdom

GenomeKey enables targeted Sepsis treatment in hours, rather than days. This is important because Sepsis now kills more people than cancer. It can hit anyone, of any age, and kills within hours. A patient admitted to a hospital today, they wait 3 days before the doctor knows which antibiotic will fight the infection. 

We use cutting edge machine learning and DNA sequencing to bring 3 days down to just a few hours, with the only affordable test that provides a result for every patient. This saves lives, saves money, and saves our last antibiotics for when we really need them.

GenomeKey

Company Details